

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 5321

**Title:** HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS UNDER ANTIVIRAL THERAPY

**Reviewer code:** 00225231

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-08-29 16:47

**Date reviewed:** 2013-09-05 16:20

| CLASSIFICATION           | LANGUAGE EVALUATION                             | RECOMMENDATION | CONCLUSION                        |
|--------------------------|---|----------------|-----------------------------------|
| [ Y] Grade A (Excellent) | [ Y] Grade A: Priority Publishing               | Google Search: | [ Y] Accept                       |
| [ ] Grade B (Very good)  | [ ] Grade B: minor language polishing           | [ ] Existed    | [ ] High priority for publication |
| [ ] Grade C (Good)       | [ ] Grade C: a great deal of language polishing | [ ] No records | [ ] Rejection                     |
| [ ] Grade D (Fair)       | [ ] Grade D: rejected                           | [ ] Existed    | [ ] Minor revision                |
| [ ] Grade E (Poor)       |   | [ ] No records | [ ] Major revision                |

## COMMENTS TO AUTHORS

This review manuscript titled “HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS UNDER ANTIVIRAL THERAPY” described the effect of antiviral therapy to the patients with chronic hepatitis B. Authors mentioned the rationale of antiviral treatment for HCC prevention and introduced the positive effect of treatment of IFNs and NAs to patients. However, it is clear that antiviral therapy reduces but does not eliminate the risk of HCC in Hepatitis B patients. It might be the integration of HBV DNA into the host genome before onset of treatment resulting in genomic alteration and /or chromosomal instability. This review manuscript is well described by providing relevant research data. I recommend this is an excellent review paper providing new insight for the understanding of presence of antiviral therapy in HBV patients to the readers of WJG.

**ESPS Peer-review Report**

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 5321

**Title:** HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS UNDER ANTIVIRAL THERAPY

**Reviewer code:** 00036318

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-08-29 16:47

**Date reviewed:** 2013-09-18 03:26

| CLASSIFICATION  | LANGUAGE EVALUATION  | RECOMMENDATION                      | CONCLUSION   |
|---|--|-------------------------------------|--|
| <input checked="" type="checkbox"/> Grade A (Excellent) | <input checked="" type="checkbox"/> Grade A: Priority Publishing     | Google Search:                      | <input checked="" type="checkbox"/> Accept             |
| <input type="checkbox"/> Grade B (Very good)            | <input type="checkbox"/> Grade B: minor language polishing           | <input type="checkbox"/> Existed    | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C (Good)                 | <input type="checkbox"/> Grade C: a great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D (Fair)                 |  | BPG Search:                         | <input type="checkbox"/> Minor revision                |
| <input type="checkbox"/> Grade E (Poor)                 | <input type="checkbox"/> Grade D: rejected                           | <input type="checkbox"/> Existed    | <input type="checkbox"/> Major revision                |
|   |  | <input type="checkbox"/> No records |  |

**COMMENTS TO AUTHORS**

This is an excellent comprehensive review written by experts in the field of chronic hepatitis B. I suggest only one small change, that the last paragraph of the conclusions be either removed or moved somewhere else in the text, since it seems rather irrelevant at that section of the text.

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 5321

**Title:** HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS UNDER ANTIVIRAL THERAPY

**Reviewer code:** 00009879

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-08-29 16:47

**Date reviewed:** 2013-09-18 12:40

| CLASSIFICATION           | LANGUAGE EVALUATION                             | RECOMMENDATION | CONCLUSION                        |
|--------------------------|---|----------------|-----------------------------------|
| [ Y] Grade A (Excellent) | [ Y] Grade A: Priority Publishing               | Google Search: | [ Y] Accept                       |
| [ ] Grade B (Very good)  | [ ] Grade B: minor language polishing           | [ ] Existed    | [ ] High priority for publication |
| [ ] Grade C (Good)       | [ ] Grade C: a great deal of language polishing | [ ] No records | [ ] Rejection                     |
| [ ] Grade D (Fair)       | [ ] Grade D: rejected                           | [ ] Existed    | [ ] Minor revision                |
| [ ] Grade E (Poor)       |   | [ ] No records | [ ] Major revision                |

## COMMENTS TO AUTHORS

The summarizes systematically the data related to impact of antiviral treatment in the prevention of HCC in patients with chronic hepatitis B. The author suggested that antiviral therapy reduce but not eliminate the risk of HCC in chronic hepatitis B patients with or without cirrhosis. Your suggestions should be considered in strategy for HCC surveillance in patients with HCC infection..

**ESPS Peer-review Report**

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 5321

**Title:** HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS UNDER ANTIVIRAL THERAPY

**Reviewer code:** 02444864

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-08-29 16:47

**Date reviewed:** 2013-09-19 20:37

| CLASSIFICATION                               | LANGUAGE EVALUATION  | RECOMMENDATION                      | CONCLUSION   |
|--|--|-------------------------------------|--|
| <input type="checkbox"/> Grade A (Excellent) | <input type="checkbox"/> Grade A: Priority Publishing                | Google Search:                      | <input type="checkbox"/> Accept                        |
| <input type="checkbox"/> Grade B (Very good) | <input type="checkbox"/> Grade B: minor language polishing           | <input type="checkbox"/> Existed    | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C (Good)      | <input type="checkbox"/> Grade C: a great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D (Fair)      | <input type="checkbox"/> Grade D: rejected                           | <input type="checkbox"/> Existed    | <input type="checkbox"/> Minor revision                |
| <input type="checkbox"/> Grade E (Poor)      |  | <input type="checkbox"/> No records | <input type="checkbox"/> Major revision                |

**COMMENTS TO AUTHORS**

Comments to the Authors This is a well written review from two experienced hepatologists providing comprehensive information on the impact of antiviral treatment in HHC prevention in patients with HBV infection. I do not have any major comment but just minor corrections . Minor comments Page 4 last paragraph: "development of HCC", repetition. Page 10: "of even lamivudine ", wrong formulation. Page 8, 2nd paragraph: " lower HHC rates", verb is missing. Pages 8 and 12 : "perhaps adefovir", unclear. Page 4: the sentence "Since all all the above....", is better to be placed at the end of this section. Page 4: the sentence "Chronic viral replication promotes release of....", should be replaced by the following "Chronic HBV infection promotes viral induced immune response with release of cytokines and genotoxic reactive oxygen species leading to liver cell necrosis as well as to activation of fibrosis cascade.